Poxvirus Targeting of E3 Ligase β-TrCP by Molecular Mimicry: A Mechanism to Inhibit NF-κB Activation and Promote Immune Evasion and Virulence

PLoS Pathogens

Volumn 9, Issue 2, 2013, Pages

  Mansur, Daniel S ^a,d   Maluquer de Motes, Carlos ^a,b   Unterholzner, Leonie ^c   Sumner, Rebecca P ^a,b   Ferguson, Brian J ^a,b   Ren, Hongwei ^a,b   Strnadova, Pavla ^a,b   Bowie, Andrew G ^c   Smith, Geoffrey L ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN A49; RANTES; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE EVASION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MOLECULAR MIMICRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; UBIQUITINATION; VACCINIA VIRUS; VIROGENESIS; VIRUS PLAQUE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; CELL LINE; I-KAPPA B KINASE; IMMUNE EVASION; MICE; MICE, INBRED BALB C; MOLECULAR MIMICRY; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; PHOSPHORYLATION; PROTEIN BINDING; UBIQUITIN-PROTEIN LIGASES; VACCINIA VIRUS; VARIOLA VIRUS; VIRULENCE;

EID: 84880946564     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003183     Document Type: Article

References (71)

1. Medzhitov R, (2009) Approaching the asymptote: 20 years later. Immunity 30: 766-775.
2. Iwasaki A, Medzhitov R, (2010) Regulation of adaptive immunity by the innate immune system. Science 327: 291-295.
3. Lawrence T, (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1: a001651.
4. Hayden MS, Ghosh S, (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
5. Oeckinghaus A, Ghosh S, (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1: a000034.
6. Brodsky IE, Medzhitov R, (2009) Targeting of immune signalling networks by bacterial pathogens. Nat Cell Biol 11: 521-526.
7. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, et al. (1995) Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 92: 10599-10603.
8. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, et al. (1997) Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J 16: 6486-6494.
9. Deshaies RJ, (1999) SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15: 435-467.
10. Kanarek N, Ben-Neriah Y, (2012) Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev 246: 77-94.
11. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1: 565-574.
12. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z, (1999) HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene 18: 2039-2046.
13. Moss B (2007) Poxviridae: the viruses and their replicaton. In: Knipe DM, editor. Fields Virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2905-2946.
14. Fenner F, Anderson DA, Arita I, Jezek Z, Ladnyi ID (1988) Smallpox and its eradication. Geneva: World Health Organisation.
15. Gubser C, Hue S, Kellam P, Smith GL, (2004) Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85: 105-117.
16. Moore JB, Smith GL, (1992) Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J 11: 3490.
17. Reading PC, Moore JB, Smith GL, (2003) Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197: 1269-1278.
18. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, et al. (2003) Poxviruses and immune evasion. Annu Rev Immunol 21: 377-423.
19. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A, (1997) Vaccinia virus immune evasion. Immunol Rev 159: 137-154.
20. Bahar MW, Graham SC, Chen RA, Cooray S, Smith GL, et al. (2011) How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 175: 127-134.
21. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, et al. (2000) A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 97: 10162-10167.
22. Harte MT, Haga IR, Maloney G, Gray P, Reading PC, et al. (2003) The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197: 343-351.
23. Stack J, Haga IR, Schroder M, Bartlett NW, Maloney G, et al. (2005) Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201: 1007-1018.
24. Benfield CT, Mansur DS, McCoy LE, Ferguson BJ, Bahar MW, et al. (2011) Mapping the IkappaB kinase beta (IKKbeta)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKbeta-mediated activation of nuclear factor kappaB. J Biol Chem 286: 20727-20735.
25. Chen RA, Jacobs N, Smith GL, (2006) Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 87: 1451-1458.
26. Graham SC, Bahar MW, Cooray S, Chen RA, Whalen DM, et al. (2008) Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4: e1000128.
27. McCoy LE, Fahy AS, Chen RA, Smith GL, (2010) Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation. J Gen Virol 91: 2216-2220.
28. DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, et al. (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279: 36570-36578.
29. Chen RA, Ryzhakov G, Cooray S, Randow F, Smith GL, (2008) Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4: e22.
30. Gedey R, Jin XL, Hinthong O, Shisler JL, (2006) Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol 80: 8676-8685.
31. Schroder M, Baran M, Bowie AG, (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27: 2147-2157.
32. Shisler JL, Jin XL, (2004) The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol 78: 3553-3560.
33. Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J, (2009) Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J Virol 83: 6757-6768.
34. Valentine R, Smith GL, (2010) Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. J Gen Virol 91: 2221-2229.
35. Ember SWJ, Ren H, Ferguson BJ, Smith GL, (2012) Vaccinia virus protein C4 inhibits NF-κB activation and promotes virus virulence. J Gen Virol 93: 2098-2108.
36. Fagan-Garcia K, Barry M, (2011) A vaccinia virus deletion mutant reveals the presence of additional inhibitors of NF-kappaB. J Virol 85: 883-894.
37. Unterholzner L, Sumner RP, Baran M, Ren H, Mansur DS, et al. (2011) Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7: e1002247.
38. Smith GL, de Carlos A, Chan YS, (1989) Vaccinia virus encodes a thymidylate kinase gene: sequence and transcriptional mapping. Nucleic Acids Res 17: 7581-7590.
39. Kerr SM, Johnston LH, Odell M, Duncan SA, Law KM, et al. (1991) Vaccinia DNA ligase complements Saccharomyces cerevisiae cdc9, localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents. Embo J 10: 4343-4350.
40. Aguado B, Selmes IP, Smith GL, (1992) Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus. J Gen Virol 73 (Pt 11): 2887-2902.
41. Assarsson E, Greenbaum JA, Sundstrom M, Schaffer L, Hammond JA, et al. (2008) Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105: 2140-2145.
42. Davison AJ, Moss B, (1989) Structure of vaccinia virus late promoters. J Mol Biol 210: 771-784.
43. Alcami A, Smith GL, (1992) A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71: 153-167.
44. Alcami A, Smith GL, (1996) A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A 93: 11029-11034.
45. Bartlett N, Symons JA, Tscharke DC, Smith GL, (2002) The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83: 1965-1976.
46. Fahy AS, Clark RH, Glyde EF, Smith GL, (2008) Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89: 2377-2387.
47. Maluquer de Motes C, Cooray S, Ren H, Almeida GM, McGourty K, et al. (2011) Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7: e1002430.
48. Reading PC, Smith GL, (2003) Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77: 9960-9968.
49. Symons JA, Adams E, Tscharke DC, Reading PC, Waldmann H, et al. (2002) The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J Gen Virol 83: 2833-2844.
50. Symons JA, Alcami A, Smith GL, (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81: 551-560.
51. Peters KL, Smith HL, Stark GR, Sen GC, (2002) IRF-3-dependent, NFkappa B- and JNK-independent activation of the 561 and IFN-beta genes in response to double-stranded RNA. Proc Natl Acad Sci U S A 99: 6322-6327.
52. Margottin-Goguet F, Hsu JY, Loktev A, Hsieh HM, Reimann JD, et al. (2003) Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell 4: 813-826.
53. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, et al. (2003) betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 23: 402-413.
54. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, et al. (2003) Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 11: 1445-1456.
55. Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, et al. (2007) Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88: 1656-1666.
56. Bour S, Perrin C, Akari H, Strebel K, (2001) The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J Biol Chem 276: 15920-15928.
57. Blanchet FP, Mitchell JP, Piguet V, (2012) beta-TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin. Curr HIV Res 10: 307-314.
58. Tscharke DC, Reading PC, Smith GL, (2002) Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83: 1977-1986.
59. Tscharke DC, Smith GL, (1999) A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80: 2751-2755.
60. Perkus ME, Goebel SJ, Davis SW, Johnson GP, Norton EK, et al. (1991) Deletion of 55 open reading frames from the termini of vaccinia virus. Virology 180: 406-410.
61. Graff JW, Ettayebi K, Hardy ME, (2009) Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism. PLoS Pathog 5: e1000280.
62. Tang W, Pavlish OA, Spiegelman VS, Parkhitko AA, Fuchs SY, (2003) Interaction of Epstein-Barr virus latent membrane protein 1 with SCFHOS/beta-TrCP E3 ubiquitin ligase regulates extent of NF-kappaB activation. J Biol Chem 278: 48942-48949.
63. Esposito JJ, Sammons SA, Frace AM, Osborne JD, Olsen-Rasmussen M, et al. (2006) Genome sequence diversity and clues to the evolution of variola (smallpox) virus. Science 313: 807-812.
64. Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M, (2007) A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics 7: 4228-4234.
65. Berrow NS, Alderton D, Sainsbury S, Nettleship J, Assenberg R, et al. (2007) A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. Nucleic Acids Res 35: e45.
66. Parkinson JE, Smith GL, (1994) Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus. Virology 204: 376-390.
67. Pirhonen J, Sareneva T, Kurimoto M, Julkunen I, Matikainen S, (1999) Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol 162: 7322-7329.
68. Jeanmougin F, Thompson JD, Gouy M, Higgins DG, Gibson TJ, (1998) Multiple sequence alignment with Clustal X. Trends Biochem Sci 23: 403-405.
69. Falkner FG, Moss B, (1990) Transient dominant selection of recombinant vaccinia viruses. J Virol 64: 3108-3111.
70. Doceul V, Hollinshead M, van der Linden L, Smith GL, (2010) Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327: 873-876.
71. Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M, (1990) Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71: 2761-2767.